Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of SLC31A1, SCO1, and COX11 in colorectal cancer

Vincenza Barresi1, Angela Trovato-Salinaro1, Giorgia Spampinato1, Nicolò Musso1, Sergio Castorina2, Enrico Rizzarelli3 and Daniele Filippo Condorelli1

1 Section of Medical Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, Italy
2 Section of Human Anatomy, Department of Biomedical and Biotechnological Sciences, University of Catania, Italy
3 Institute of Biostructures and Bioimaging, National Council of Research, UOS Catania, Italy

Keywords
alternative transcripts; colorectal cancer; copper homeostasis; copper transporter; synthesis of cytochrome c oxidase

Correspondence
D. F. Condorelli, Section of Medical Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 64, 95125 Catania, Italy Fax/Tel: +39 095 7384256 E-mail: daniele.condorelli@unict.it

(Received 1 October 2015, revised 6 February 2016, accepted 17 March 2016)
doi:10.1002/2211-5463.12060

Copper homeostasis and distribution is strictly regulated by a network of transporters and intracellular chaperones encoded by a group of genes collectively known as copper homeostasis genes (CHGs). In this work, analysis of The Cancer Genome Atlas database for somatic point mutations in colorectal cancer revealed that inactivating mutations are absent or extremely rare in CHGs. Using oligonucleotide microarrays, we found a strong increase in mRNA levels of the membrane copper transporter 1 protein [CTR1; encoded by the solute carrier family 31 member 1 gene (SLC31A1 gene)] in our series of colorectal carcinoma samples. CTR1 is the main copper influx transporter and changes in its expression are able to induce modifications of cellular copper accumulation. The increased SLC31A1 mRNA level is accompanied by a parallel increase in transcript levels for copper efflux pump ATP7A, copper metabolism Murr1 domain containing 1 (COMMD1), the cytochrome C oxidase assembly factors [synthesis of cytochrome c oxidase 1 (SCO1) and cytochrome c oxidase copper chaperone 11 (COX11)], the cupric reductase six transmembrane epithelial antigen of the prostate (STEAP3), and the metal-regulatory transcription factors (MTF1, MTF2) and specificity protein 1 (SP1). The significant correlation between SLC31A1, SCO1, and COX11 mRNA levels suggests that this transcriptional upregulation might be part of a coordinated program of gene regulation. Transcript-level upregulation of SLC31A1, SCO1, and COX11 was also confirmed by the analysis of different colon carcinoma cell lines (Caco-2, HT116, HT29) and cancer cell lines of different tissue origin (MCF7, PC3). Finally, exon-level expression analysis of SLC31A1 reveals differential expression of alternative transcripts in colorectal cancer and normal colonic mucosa.

Abbreviations
ATOX1, antioxidant 1 copper chaperone; CCS, copper chaperone for SOD1; CHGs, copper homeostasis genes; COMMD1, copper metabolism Murr1 domain containing 1; COX11, cytochrome c oxidase copper chaperone 11; COX17, cytochrome c oxidase copper chaperone 17; CRC, colorectal cancer; CTR1, membrane copper transporter 1 protein; gDNA, genomic DNA; MSI, microsatellite instability; MTF1, MTF2, metal-regulatory transcription factors; MTs, metallothioneins; PSR, probe selection region; RMA, robust multi-array average; RPKM, reads per kilobase of transcript per million mapped reads; SCO1, synthesis of cytochrome c oxidase 1; SCO2, synthesis of cytochrome c oxidase 2; SD, standard deviation; SLC31A1, solute carrier family 31 member 1 gene (encoding CTR1 protein); SP1, transcription factor or specificity protein 1; STEAP, six transmembrane epithelial antigen of the prostate; TAC, Affymetrix® Transcriptome Analysis Console Software; TCGA, The Cancer Genome Atlas; TNM, tumor-node-metastasis.
A classical approach in the search of anticancer therapies is based on the exploitation of quantitative and qualitative differences in biochemical processes between tumor and normal cells [1–3]. Copper assumes a critical role in many biological processes, mainly as a catalytic cofactor of enzymes, [4] and its homeostasis is guaranteed by the activity of metal transporters and intracellular chaperones [5–7]. In humans, disruption of this tightly regulated cellular copper homeostasis affects normal tissue development and a growing number of reports indicates an alteration of essential metal ion homeostasis (metallostasis) in tumors [8,9].

The ‘membrane copper transporter 1’ (CTR1) protein, encoded by the solute carrier family 31 member 1 (SLC31A1) gene, is generally considered as responsible for cellular copper uptake in all cells [10]. Cu(I) is transported by CTR1 and reduction of extracellular Cu(II) to Cu(I) is catalyzed by a family of metalloreductases called ‘six transmembrane epithelial antigens of the prostate’ (STEAP). Four members of this protein family have been identified and it has been demonstrated that three of them, STEAP2, STEAP3, and STEAP4, are cupric reductases that stimulate copper cellular uptake [11].

The ‘antioxidant 1 copper chaperone’ (ATOX1) [12], the ‘copper chaperone for SOD1’ (CCS) [13], the ‘cytochrome c oxidase copper’ chaperones COX17 and COX11 [14,15], and the mitochondrial cytochrome c oxidase assembly proteins called ‘synthesis of cytochrome c oxidase’ (SCO1 and 2) [16] bind Cu(I) facilitating its transfer to specific cellular destinations. Copper is transferred by CCS to the cuproenzyme SOD1 or by SCO1, SCO2, COX11, and COX17 to cytochrome c oxidase. ATOX1 is responsible for the transfer of copper to exporting ATPase pumps (ATP7A/B”) [17,18]. ‘Copper metabolism Murr1 domain containing 1’ (COMMD1) is another protein that facilitates the efflux of copper probably via its interaction with the copper transporter ATP7B and ATP7A [19].

Copper can be detoxified by the metallothioneins (MTs), a family of small proteins (7 kDa) containing a high proportion of cysteins. Thiold groups of the MTs can bind metal ions with high affinity acting as a buffer system or a reservoir for essential copper and zinc ions [20].

In this study, we analyzed the profile of somatic mutations and the expression of the above-mentioned genes involved in copper homeostasis (copper homeostasis genes: CHGs) in colorectal cancer (CRC) samples and normal colonic mucosa (Mu). Results show a series of significant changes in the expression levels of several CHGs that could be interpreted as the consequence of an intense activity of this functional network. In particular, a correlated upregulation of SLC31A1, SCO1, and COX11 mRNA has been observed in cancer cells in vivo and in culture conditions.

Materials and methods

Patients

Twenty-seven patients underwent surgical resection for primary invasive colorectal cancer at the ‘Centro Clinico Diagnostico G.B. Morgagni’ in Catania. Tumors were staged according to the tumor-node-metastasis (TNM) staging system of UICC. The mean age was 66.61 years (SD 16.31) for 18 male patients and 68.67 (SD 15.63) for nine female patients. The tumors were mainly in stage II or III. In 19 patients, a sample of the matched unaffected normal colonic mucosa was also taken at distance of 3–6 cm from the tumor. All CRC specimens were frozen and stored at –80 °C until to RNA extraction. Informed consent was obtained from all patients involved in this study. This project was approved by the Ethics Committee of ASL3 of Catania (Italy).

RNA extraction

Total RNA was extracted from tissue and cell lines using RNeasy Mini Kit (Cat. No. 74104; Qiagen, Milan, Italy) according to the manufacturer’s instructions. The concentration and the quality of the RNA were determined using a ND-1000 spectrophotometer (NanoDrop, Thermo Scientific, Pero, Italy).

Transcriptome analysis

Whole Transcript Expression analysis was performed using 100 ng of total RNA to produce amplified, and targets labeled in sense orientation for hybridization to the ‘GeneChip Human Transcriptome Array 2.0’ according to the protocol supplied by the manufacturer (Cat. No. 902310, Cat. No. 900720; Affymetrix UK Ltd., High Wycombe, UK). Human Transcriptome Array 2.0 contains > 6.0 million distinct probes for analyzing simultaneously 44 699 coding transcripts and 22 829 noncoding transcripts. Array scanning and data analysis were performed using affymetrix® expression console™ software (v.1.4; Affymetrix UK Ltd.) that provides signal estimation and quality control functionality for the GeneChip® Expression Arrays, and the affymetrix® transcriptome analysis console (TAC) Software (Affymetrix UK Ltd.), which performs statistical analysis and provides a list of differentially expressed genes. Expression level analysis was performed using the normalization method based on
the processing algorithm called robust multi-array average (RMA) [21].

The data have been deposited to public repository: ‘Gene Expression Omnibus-GEO’ (www.ncbi.nlm.nih.gov/geo) and will be accessible through GEO: GSE73360.

Cell cultures

Three human colorectal adenocarcinoma cell lines (Caco-2, HT29, and HCT116) and two human noncolorectal adenocarcinoma cell lines (MCF7 and PC3) have been used in the present work. Human colon cancer Caco-2 (ATCC number: HTB-37) and HT29 (ATCC number: HTB-38) cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM 1X; Gibco, Cat No. 31965-023 containing 4.5 g L⁻¹ of D-glucose). The HCT116 (ATCC number: CCL-247) cell line was cultured in McCoy 5A⁺ (McCoy’s 5A Medium 1X Gibco, Cat No. 36600-021 containing 3 g L⁻¹ of D-glucose), 1.5 mM L-glutamine and 2200 mg L⁻¹ of sodium bicarbonate. The human breast adenocarcinoma cell line MCF-7 (ATCC number: HTB-22) was maintained in DMEM medium (1X; Gibco, Cat No. 31965-023 containing 1 g L⁻¹ of D-glucose). The human prostate adenocarcinoma cell line PC3 (ATCC number: CRL-1435) cell line was grown in DMEM/F12 medium nutrient mixture (1X; Gibco, Cat No. 21331-020) and 1.5 mM L-glutamine. Each medium was supplemented with 10% FBS (Cat. No. 10270-106; Life Technologies, Monza, Italy) and 100 U mL⁻¹ of penicillin-streptomycin (Cat. No 15140-122; Life Technologies). The cell cultures were grown in flasks (75 cm²) and incubated at 37 °C in humidified atmosphere with 5% of CO₂ and 95% of air. The culture medium was changed twice a week.

MicroSatellite Instability analysis

Genomic DNA (gDNA) was extracted from each tissue using the DNeasy Blood & Tissue Kit (Cat. No. 69504; Qiagen) according to the manufacturer’s instructions. The concentration and the quality of the DNA were determined using a ND-1000 spectrophotometer (NanoDrop, Thermo Scientific)

Microsatellite instability (MSI) analysis was performed on matched samples of DNA (100 ng) obtained from CRC tumors and adjacent normal colonic tissue by fluorescent dye-labeled PCR amplification using a panel of six microsatellite markers: four of them belonging to Bethesda panel (D2S123, D5S346, BAT25, and BAT26) together with two additional microsatellite markers (D17S250 and BAT40). PCR amplification was conducted using primer sequences previously reported by Dietmaier et al. [22].

5’-Fluorescent dye-labeled (NED for BAT25, VIC for BAT26, 6-FAM for BAT40, PET for DSS346, FAM for D2S123, and VIC for D18S58) and unlabeled oligonucleotides were used for PCR reactions and the amplification products were analyzed by ABI PRISM 310 genetic analyzer using GENESCAN ANALYSIS Software (Applied Bionsystems, Monza, Italy).

International criteria for the determination of MSI in CRC were used to differentiate high instability (MSI-H) from low instability (MSI-L) or microsatellite stability (MSS). Tumors were defined as MSI-H if two or more of the six microsatellite markers show instability; MSI-L if only one of the six markers shows instability; and microsatellite stable (MSS) if none of the markers show instability. Since MSI-L have clinical and biological feature similar to MSS tumors [23], they have been included in the MSS group in all the analysis. Therefore, in the rest of the paper, the abbreviation MSI has been used to indicate MSI-H and the term MSS to indicate MSS and MSI-L tumors. MSI status was successfully determined in all tumors and the analysis revealed that 22 tumors were MSS (8 females and 14 males) and five tumors were MSI (1 female and 4 males).

Publicly available datasets of RNAseq and microarray data

The Cancer Genome Atlas (TCGA) data portal [24] provides transcriptomic data on 287 colon adenocarcinoma samples and 24 matched normal tissues obtained by IlluminaHiSeq_RNASeqV2 technology (https://tcga-data.nci.nih.gov/tcga/). Transcript abundances were calculated in reads per kilobase of transcript per million mapped reads (RPKM).

Microarray data (GEO: GSE24550, deposited by Agesen et al. [25]) were downloaded from the NCBI’s Gene Expression Omnibus [26]. The data were obtained from 77 CRCs and 13 normal colonic mucosa samples using the Affymetrix Human Exon 1.0 ST platform (Affymetrix, Santa Clara, CA, USA).

Results

Somatic point mutations of CHGs in colorectal tumors

In order to evaluate if inactivating point mutations of CHGs can be responsible for dysfunctions of copper homeostasis, The Cancer Genome Atlas Dataset (Cancer Genome Atlas Network, 2012) was analyzed. Data on point mutations detected by exome sequencing of 228 tumors and normal pairs are reported in such data set. In Fig. 1A,B the number of nonsense, frameshift, and missense mutations for CHGs are reported. The frequency of point mutations in CHGs is very low when compared with typical cancer gene drivers, such as ‘phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha’ (PIK3CA). Therefore, these data do not support the hypothesis that accumulation of somatic mutations in CHGs can be responsible for a copper dyshomeostasis in CRC.

mRNA levels of CHGs in colorectal tumors

As shown in Fig. 2 (linear fold changes) and Fig. 3A, C (RMA values) the mRNA for the copper transporter CTR1 (SLC31A1 gene) is dramatically increased (6.72-fold increase) in tumoral samples in comparison to normal colonic mucosae. Several other CHGs show a significant increase in tumoral samples: the efflux pumps ATP7A and B (1.5- and 1.31-fold); the copper assembly factors SCO1 (1.98-fold) and COX11 (1.6-fold); the metalloreductase STEAP3 (1.49-fold); the copper efflux protein COMMD1 (1.33-fold); and the transcription factors MTF1, MTF2 (1.78- and 1.54-fold), and SP1 (2.58). The cuproenzyme SOD1 (5.14-fold) and the manganese enzyme SOD2 (3.4-fold) are dramatically upregulated in CRC. Only STEAP4 shows a slight (−1.3-fold) but
Copper homeostasis genes in colorectal cancer
V. Barresi et al.

A statically significant decrease of expression in the CRC sample group in comparison to normal colonic mucosae.

Similar changes are also detected in three colon cancer cell lines (Caco-2, HT29, and HCT116) and in two cancer cell lines of different tissue origin (breast cancer cell line MCF7 and prostate cancer cell line PC3) (Fig. 4). In particular, the large increase in SLC31A1/CTR1 mRNA and the significant increase in SCO1 and COX11 mRNAs are present in all examined cell lines.

Based on a form of genetic instability, called microsatellite instability, CRC can be subdivided in two different classes; tumors with MSS and tumors with MSI. Microsatellites are tract of repetitive DNA formed by an individually fixed number of repeating units of 1–4 nucleotides. It is well-known that a subgroup of CRC (10–15%) show a somatic variability in repeating units in cancer cells (MSI tumors). The presence of this form of genetic instability is associated with several biological feature of the tumor and with a better prognosis [23,27]. In our CRC samples, both MSS and MSI tumors show an increased expression of SLC31A1/CTR1, SCO1, and COX11 (Fig. 5). Values are slightly higher in MSI tumors but these differences are not statistically significant.

As shown in Fig. 6 a significant correlation between SLC31A1 (encoding CTR1), COX11, and SCO1 mRNA levels can be observed in CRC samples, suggesting that the transcriptional upregulation of these CHGs is part of a coordinated program of gene regulation.

Exon-level expression analysis of SLC31A1 transcripts

In this study, transcript levels were determined by the Gene-Chip Human Transcriptome Array 2.0 (Affymetrix). This high resolution array was designed with approximately ten probes per exon and four probes...
The exon-level analysis of SLC31A1 is reported in Table 1A and in Fig. 7. The upregulation of SLC31A1 involves the five exons (1, 2, 3, 4, and 5) that have been included in the classical structure of this gene (Fig. 8) [10,28,29]. This concordance with the classical exon–intron structure of the gene is in favor of the synthesis of a functional protein in colorectal cancer. However, differences in the upregulation level of the different exons are also observed. The highest differences in RMA values between CRC and normal colonic mucosae (see also fold-change values in Table 1A) are observed at the level of exon 3, 4, and 5b, and less differences are observed at the level of exon 1, 2, and 5d. The relatively high expression of exon 1 and 2 in the normal colonic mucosa might be explained by the expression of an alternative transcripts containing exon

The TAC software provides a comparison of the alternative splicing analysis using default parameters. The TAC software provides a comparison of the expression of each exon (corresponding to a probe selection region, PSR) in two different conditions (in this work, CRC vs normal colonic mucosae). Such comparison is obtained by the so called ‘splicing index’: (intensity of exon X in CRC/intensity of gene Y in CRC)/(intensity of exon X in normal colonic mucosae/intensity of gene Y in normal colonic mucosae). Therefore, a positive index is obtained for exons prevalently expressed in cancer cells, while a negative one indicates a prevalent expression in normal colonic cells.
1 and 2, but not exon 3 and 4, as also suggested by the significant negative splicing index (Table 1A, Fig. 7). This might be a functionally relevant observation as exon 2 encodes for the amino-terminal part of the protein. On the contrary, the splicing index for exon 3, 4, and 5b is positive, a result that can be due to a prevalent expression of transcripts containing these exons in CRC.

These results were confirmed by the comparison of cancer cell lines (Caco-2, HT29, HCT116) versus the same set of normal colonic mucosae (Table 1B).

**Exon-level expression analysis of SLC31A1 transcripts in different publicly available datasets**

We also analyzed different publicly available datasets in order to confirm changes of SLC31A1 gene expression in colorectal cancer. TCGA (2012) provides transcriptomic data on 287 colon cancer samples and 24 matched normal tissues obtained by RNA-seq technology (https://tcga-data.nci.nih.gov/). A significant increase in RPKM values relative to exon 3 and 5 of SLC31A1 can be detected (Fig. 9A). However, the fold-increase values are much lower than those observed in HTA microarray.

In order to make a comparison with a more similar methodology, we downloaded expression microarray raw data from the Gene Expression Omnibus (GEO) public repository. In the series, GEO: GSE24550 [25] exon-level data from 77 CRCs and 13 normal colonic mucosa sample have been obtained by the Affymetrix Human Exon 1.0 ST platform. Data analysis of .cel files were performed using AFFYMETRIX® EXPRESSION CONSOLE™ software v.1.4 and the AFFYMETRIX® TRANSCRIPTOME
ANALYSIS CONSOLE (TAC) software. As shown in Fig. 9B, a significant increase in RMA values was observed at the level of SLC31A1 exon 2–5. In accordance with RNA-seq data, the fold change increases (+ 40%) were lower than those observed in our HTA analysis. Such data are in agreement with an increase in SLC31A1 transcript level, but dramatic differences in the fold-change expression levels are revealed between HTA arrays and previous version of exon arrays or different methodologies, such as RNA sequencing.

### Table 1.

(A) Exon-level analysis of SLC31A1/CTR1 gene: comparison between CRC samples and normal colonic mucosae (Mu). (B) Exon-level analysis of SLC31A1/CTR1 gene: comparison between CRC cell lines and normal colonic mucosae (Mu).

| Exon | PSR       | mRNA/Protein | CRC RMA value | Mu RMA value | Fold change | Splicing Index | Splicing Index FDR |
|------|-----------|--------------|---------------|--------------|-------------|----------------|-------------------|
| (A)  | 1         | 5' UTR       | 12.79         | 11.24        | 2.92        | −5.18          | 0.000105          |
|      | 2alt      | ?            | 6.44          | 6.7          | −1.2        | −16.28         | 0.000001          |
|      | 2         | 5'UTR.CDS/aa 1-43 | 11.32         | 9.43         | 3.72        | −3.25          | 0.000764          |
|      | 3         | CDS/aa 44-68 | 12.57         | 7.24         | 40.26       | 1.52           | 0.041754          |
|      | 4         | CDS/aa 69-124| 12.27         | 6.94         | 40.23       | 1.52           | 0.002176          |
|      | 5a        | CDS/aa 125-136| 10.78        | 7.38         | 10.57       | −1.10          | 0.561023          |
|      | 5b        | CDS.3'UTR/aa 137-190| 13.04       | 7.77         | 38.58       | 1.80           | 0.000198          |
|      | 5d        | 3' UTR       | 9.05          | 6.97         | 4.23        | −3.48          | 0.001273          |
|      | 5c        | 3' UTR       | 10.24         | 6.91         | 10.01       | −1.88          | 0.003033          |
| (B)  | 1         | 5' UTR       | 15.92         | 11.24        | 25.57       | −6.61          | 0.000119          |
|      | 2alt      | ?            | 6.31          | 6.70         | −1.31       | −268.75        | 0.00000002         |
|      | 2         | 5'UTR. CDS/aa 1-43 | 14.40        | 9.43         | 31.37       | −5.76          | 0.00044           |
|      | 3         | CDS/aa 44-68 | 16.24         | 7.24         | 513.07      | 2.15           | 0.021             |
|      | 4         | CDS/aa 69-124| 16.13         | 6.94         | 580.95      | 1.99           | 0.018             |
|      | 5a        | CDS/aa 125-136| 14.28        | 7.38         | 119.71      | −1.33          | 0.500             |
|      | 5b        | CDS.3'UTR/aa 137-190*| 15.97       | 7.77         | 294.54      | 1.21           | 0.408             |
|      | 5d        | 3' UTR       | 9.94          | 6.97         | 7.83        | −12.78         | 0.000004          |
|      | 5c        | 3' UTR       | 10.21         | 6.91         | 9.86        | −5.51          | 0.000008          |

Fig. 7. Gene Structure View of SLC31A1/CTR1 (TAC software). All PSRs and Junctions are represented with boxes. The first two lines from the top display, in azure/orange scale, the RMA values for each PSR and corresponding exons: top line for CRC and middle line for normal mucosae (Mu). The bottom line displays the splicing index in a green/red scale.
Discussion

Theoretically, accumulation of somatic mutations in cancer cells can modify a functional network with two different mechanisms: (a) a direct mechanism in which loss-of-function or gain-of-function somatic mutations affect genes whose products are mainly involved in a specific function, (b) an indirect mechanism in which somatic mutations take place in genes involved in signaling and regulatory factors able to induce alterations of multiple functional networks. Both types of mutations can be selected during the process of cancerogenesis if they are advantageous for tumor growth. With this in mind, in the present work, we try to answer some basic questions regarding mutational profile and gene expression of the functional network involved in copper trafficking and homeostasis pathways [4,5] in colorectal cancer.

As a first step, we investigated the presence of somatic mutation in CHGs using the public database of somatic point mutations in CRC of The Cancer Genome Atlas Network (2012). Such analysis revealed that inactivating mutations are absent or extremely rare in genes encoding proteins involved in copper homeostasis. This observation suggests that inactivating mutations are negatively selected during the cancerogenesis process since these proteins play a fundamental role in cell survival.

In a second step, we analyzed, at the mRNA level, the expression of CHGs in our series of colorectal carcinoma samples, showing an upregulation of several components of this functional pathway. In particular, we found a strong increase in mRNA levels of the copper transporter CTR1. Analysis of different publicly available gene expression datasets, obtained by RNA-seq or previous version of Affymetrix exon microarray, confirmed a significant higher expression of SLC31A1 transcripts in CRC, but revealed only weak changes compared to results obtained by HTA.
arrays. The reason for such quantitative difference is not clear at the moment and further research on gene expression normalization methods might shed light on this discrepancy.

CTR1 is the main Cu influx transporter in human cells and it has been shown that changes in its expression are able to induce modifications of cellular copper accumulation and resistance to copper cytotoxic effect [30–32]. Unlike CTR1, the transcript for the low-affinity copper transporter, CTR2, does not show any significant change in CRC. This observation is in agreement with the difference in function and regulation of expression between the two copper transporters [33]. The observed CTR1 mRNA upregulation can be interpreted suggesting that cancer cells have a greater demand for copper than normal cells and that this requirement is linked to their proliferation and survival.

One of the limits of this investigation is the absence of data on CTR1 at the protein level. However, several studies show that transcriptional upregulation of the SLC31A1 gene translates in higher protein levels and functional copper uptake [32,34,35]. Moreover, an upregulation of CTR1 protein has been observed in a mouse model of HPV16-induced cervical carcinoma. In this model, the CTR1 protein is highly expressed in tumors but not in the epithelium of the wild-type cervix, the origin of cervical carcinoma [36]. It is also relevant that CTR1 is required for ‘fibroblast growth factor’ (FGF), platelet-derived growth factor (PDGF), and epidermal growth factor (EGF)-induced mitogen-activated protein kinase (MAPK) signaling [37] and that copper influx through CTR1 is required for oncogenic B-Raf proto-oncogene, serine/threonine kinase (BRAF) signaling and tumorigenesis [38,39].

Few data regarding protein level of CTR1 in human cancer samples are available in the literature. Holzer et al. [40] have determined the pattern of CTR1 protein expression in normal and malignant human tissues using standard immunohistochemical techniques. No CTR1 expression was found in several common types of cancer, although metastatic colon carcinoma showed the highest level of expression among the malignant tissues [40]. More recently Kim et al. [41] could detect the expression of CTR1 by immunohistochemistry in several samples of nonsmall cell lung cancer and corresponding normal epithelium.

A correlation between higher hCTR1 levels and higher platinum drug uptake in tumor cells sensitive to the drug has been reported [30–32,36,41]. The observation that CTR1 expression is upregulated at similar levels in MSI and MSS tumors would suggest a sensitivity of both types of CRC to platinum drugs. Indeed, it has been reported that sensitivity to oxaliplatin was independent of the MSI status in CRC cell lines [42] and current clinical data suggest that MSI CRC may be sensitive to oxaliplatin [23].

The exon-level comparison of SLC31A1 transcripts in CRC and normal colonic mucosae suggests the possible existence of novel alternative transcripts and a different quantitative distribution of SLC31A1 alternative transcripts in normal and cancer cells. Although the exact structure of novel alternative transcripts should be determined in future studies, these data are essential for the design of novel assays for the quantitative determination of CTR1 transcript level in cancer cells.

The increased SLC31A1 mRNA level is accompanied by a parallel increase in transcript levels for copper efflux pump ATP7A, the copper assembly factor SCO1 and COX11, the cupric reductase STEAP3, and the transcription factors MTF1, MTF2, and Sp1. Such mRNA changes are highly correlated suggesting that they might be part of a coordinated transcriptional program. In this sense, the significant correlations between CTR1 (SLC31A1 gene), SCO1, and COX11 mRNA levels suggest that such transcriptional upregulation might be part of a gene regulation program associated with cancer proliferation.

The transcriptional upregulation of copper transporters and chaperones in proliferating cells can be interpreted as a functional hyperactivity of copper trafficking pathways. Indeed, the observed transcriptional upregulation of the cuproenzyme SOD gene is coherent with an increase requirement and delivery of copper to intracellular sites. The observation that such coordinated transcriptional program is also conserved in the artificial growth conditions of the colon cancer cell lines suggests that it might represent a basic feature of proliferating cancer cells. This is also supported by the increased expression of SLC31A1, SCO1, and COX11 mRNA observed in cell lines with a different tissue origin, such as MCF7 (breast cancer) and PC3 (prostate cancer).

A notable exception to the increased level of CHGs is represented by the copper chaperones ATOX1 and CCS. Although it is possible that other mechanisms of post-translational regulation are operative for these proteins [43,44], this aspect has not been further investigated in this study. Moreover, it has been reported that CTR1 silencing increases and copper supplementation decreases the protein level of ATOX1 and CCS [44]. It is, therefore, conceivable that CTR1 overexpression in CRC is not accompanied by a parallel increase in ATOX1 and CCS mRNAs.

Our data are in agreement with previous results by Ishida et al. [45], suggesting that cancer cells might
Copper homeostasis genes in colorectal cancer

V. Barresi et al.

have a greater demand for and dependence upon copper. These researchers have observed increased levels of the copper transporter Ctr1 protein in mouse cervical carcinoma [36] and increased Ctr1 mRNA levels in islets undergoing tumorigenesis [45]. Moreover, the same research group has shown that the activity of cytochrome c oxidase, a key enzyme in oxidative phosphorylation, in tumors is affected by copper chelating treatment [45]. Interestingly, in the present work, we found a parallel transcriptional upregulation of CTR1 and the metallochaperones SCO1 and COX11 involved in the assembly of cytochrome c oxidase [46]. COX11 and SCO1 are core metallochaperones assisting Cox17 in the copper insertion in cytochrome c oxidase. Copper metalation of the CuB site in the subunit 1 of cytochrome oxidase (Cox1) requires Cox11, while the metallochaperone SCO1 interacts with the subunit 2 of cytochrome oxidase (Cox2) to facilitate the maturation of its CuA site. It has been postulated that SCO1 mediates Cu(I) transfer from Cox17 to Cox2. Moreover, it has been recently shown a novel functional connection between SCO1 and CTR1; CTR1 is rapidly degraded in the absence of SCO1 protein, and its levels are restored in Scol−/− mouse embryonic fibroblasts upon inhibition of the proteasome [47]. Therefore, a functional synergy between CTR1 and SCO1 may meet the higher copper demand by CRC cells.

In conclusion, our results provide fundamental information on the transcript-level expression of CHGs in colorectal cancer and further support the hypothesis that a subgroup of such cancers are characterized by a higher copper demand [45].

Author contributions

ATS and GS carried out RNA extraction, transcriptome analysis and cell cultures. NM carried out cell cultures and microsatellite instability analysis. VB and DFC designed, planned and coordinated the study, interpreted the data, wrote the manuscript. VB, GS, ATS and DFC deposited the microarray data and prepared figures. SC carried out the surgery, the dissection of cancer samples and contributed to the interpretation of results. ER contributed to the planning of the study and the interpretation of results. All authors read and approved the final version of the manuscript.

References

1 Barresi V, Romano A, Musso N, Capizzi C, Consoli C, Martelli MP, Palumbo GA, Di Raimondo F and Condorelli DF (2010a) Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes. Genes Chromosom Cancer 49, 1014–1023.
2 Barresi V, Palumbo GA, Musso N, Consoli C, Capizzi C, Meli CR, Romano A, Di Raimondo F and Condorelli DF (2010b) Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML. Leuk Res 34, 1539–1542.
3 Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L et al. (2012) Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337–342.
4 Festa RA and Thiele DJ (2011) Copper: an essential metal in biology. Curr Biol 21, R877–R883.
5 Lutsenko S (2010) Human copper homeostasis: a network of interconnected pathways. Curr Opin Chem Biol 14, 211–217.
6 Robinson NJ and Winge DR (2010) Copper metallochaperones. Annu Rev Biochem 79, 537–562.
7 Harrison MD, Jones CE, Solioz M and Dameron CT (2000) Intracellular copper routing: the role of copper chaperones. Trends Biochem Sci 25, 29–32.
8 Margalioth EJ, Schenker JG and Chevion M (1983) Copper and zinc levels in normal and malignant tissues. Cancer 52, 868–872.
9 Diez M, Cerdán FJ, Arroyo M and Balibrea JL (1989) Use of the copper/zinc ratio in the diagnosis of lung cancer. Cancer 63, 726–730.
10 Ohrvik H and Thiele DJ (2014) How copper traverses cellular membranes through the mammalian copper transporter 1, Ctr1. Am N Y Acad Sci 1314, 32–41.
11 Gomes IM, Maia CJ and Santos CR (2012) STEAP proteins: from structure to applications in cancer therapy. Mol Cancer Res 10, 573–587.
12 Klomp LW, Lin SJ, Yuan DS, Klausner RD, Culotta VC and Gitlin JD (1997) Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J Biol Chem 272, 9221–9226.
13 Culotta VC, Klomp LW, Strain J, Casareno RL, Krems B and Gitlin JD (1997) The copper chaperone for superoxide dismutase. J Biol Chem 272, 23469–23472.
14 Punter FA, Adams DL and Glerum DM (2000) Characterization and localization of human COX17, gene involved in mitochondrial copper transport. Hum Genet 107, 69–74.
15 Carr HS, Maxfield AB, Horng YC and Winge DR (2005) Functional analysis of the domains in Cox11. Biol Chem 280, 22664–22669.
16 Leary SC, Kaufman BA, Pellecchia G, Guercin GH, Mattman A, Jakusch M and Shoubridge EA (2004)
Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase. *Hum Mol Genet* **13**, 1839–1848.
17 Yamaguchi Y, Heiny ME, Suzuki M and Gitlin JD (1996) Biochemical characterization and intracellular localization of the Menkes disease protein. *Proc Natl Acad Sci USA* **93**, 14030–14035.
18 Petrukhin K, Lutsenko S, Chernov I, Ross BM, Kaplan JH and Gilliam TC (1994) Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. *Hum Mol Genet* **3**, 1647–1656.
19 Maine GN, Mao X, Muller PA, Komarck CM, Klomp Zalewska M, Trefon J and Milnerowicz H (2014) The role of metallothionein interactions with other proteins. *Proteomics* **14**, 1343–1356.
20 Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* **4**, 249–264.
21 Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R and Rüschhoff J (1997) Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. *Cancer Res* **57**, 4749–4756.
22 Kawakami H, Zaanan A and Sinicrope FA (2015) Microsatellite instability testing and its role in the management of colorectal cancer. *Curr Treat Options Oncol* **16**, 30.
23 The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. *Nature* **487**, 330–337.
24 Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheco RT and Lothe RA (2012) ColoGuideEx: a robust gene classifier for stage II colorectal cancer prognosis. *Gut* **61**, 1560–1567.
25 Edgar L, Domrachev M and Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res* **30**, 207–210.
26 Boland CR and Goel A (2010) Microsatellite Instability in Colorectal Cancer. *Gastroenterology* **138**, 2073–2087.e3.
27 Lee J, Prohaska JR, Dagenais SL, Glover TW and Thiele DJ (2000) Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. *Gene* **254**, 87–96.
28 Kim H, Wu X and Lee J (2013) SLC31 (CTR) family of copper transporters in health and disease. *Mol Aspects Med* **34**, 561–570.
29 Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R and Howell SB (2004) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. *Mol Pharmacol* **66**, 817–823.
30 Kawakami H, Zaanan A and Sinicrope FA (2015) Mechanistic comparison of human high affinity copper transporter 1-mediated transport between copper ion and cisplatin. *Mol Pharmacol* **76**, 843–853.
31 Kuo MT, Fu S, Savaraj N and Chen HH (2012) Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. *Cancer Res* **72**, 4616–4621.
32 Blair BG, Larson CA, Adams PL, Abada PB, Safaei R and Howell SB (2010) Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. *Mol Pharmacol* **77**, 912–921.
33 Lin X, Shang X, Manorek G, Fofana M and Stephen BH (2014) Integrin aV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter. CTR1. *Oncoscience* **1**, 185–195.
34 Song I, Chen H, Aiba I, Hospain A, Liang Z, Klomp L and Kuo M (2008) Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. *Mol Pharmacol* **74**, 705–713.
35 Ishida S, McCormick F, Smith-McCune K and Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. *Cancer Cell* **17**, 574–583.
36 Tsai CY, Finley JC, Ali SS, Patel HH and Howell SB (2012) Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. *Biochem Pharmacol* **84**, 1007–1013.
37 Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikaud A, Knapp S, Xiao K, Campbell SL, Thiele DJ et al. (2014) Copper is required for oncogenic BRAF signalling and tumorigenesis. *Nature* **509**, 492–496.
38 Turski ML, Brady DC, Kim HJ, Kim BE, Nose Y, Counter CM, Winge DR and Thiele DJ (2012) A novel role for copper in Ras/mitogen-activated protein kinase signaling. *Mol Cell Biol* **32**, 1284–1295.
39 Holzer AK, Varki NM, Le QT, Gibson MA, Naredi P and Howell SB (2006) Expression of the human copper influx transporter 1 in normal and malignant human tissues. *J Histochem Cytochem* **54**, 1041–1049.
40 Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II et al. (2014) Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. *Lung Cancer* **85**, 88–93.
41 Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD and Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. *Cancer Res* **56**, 4881–4886.
43 van den Berghe PV and Klomp LW (2010) Post-translational regulation of copper transporters. *J Biol Inorg Chem* **15**, 37–46.

44 Dong D, Xu X, Yin W and Kang YJ (2014) Changes in copper concentrations affect the protein level but not the mRNA levels of copper chaperones in human umbilical vein endothelial cells. *Metallomics* **6**, 554–559.

45 Ishida S, Andreux P, Poitry-Yamate C, Auwerx J and Hanahan D (2013) Bioavailable copper modulates oxidative phosphorylation and growth of tumors. *Proc Natl Acad Sci USA* **110**, 19507–19512.

46 Cobine PA, Pierrel F and Winge DR (2006) Copper trafficking to the mitochondrion and assembly of copper metalloenzymes. *Biochim Biophys Acta* **1763**, 759–772.

47 Hlynialuk CJ, Ling B, Baker ZN, Cobine PA, Yu LD, Boulet A, Wai T, Hussain A, El Zawily AM, McFie PJ *et al.* (2015) The mitochondrial metallochaperone SCO1 is required to sustain expression of the high-affinity copper transporter CTR1 and preserve copper homeostasis. *Cell Rep* **10**, 933–943.